Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Statements of Operations

v3.22.1
Unaudited Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2022
Mar. 31, 2021
Operating expenses:        
Research and development $ 8,686 $ 3,758 $ 23,912 $ 10,598
General and administrative 2,068 1,725 6,632 5,660
Total operating expenses 10,754 5,483 30,544 16,258
Operating loss (10,754) (5,483) (30,544) (16,258)
Non-operating income (expense):        
Interest expense (442)   (1,329)  
Gain (loss) from change in fair value of derivative liabilities (12) 1,784 (8) 1,784
Employee retention credit     231  
Interest and other income   4 13 62
Total non-operating income (expense), net (454) 1,788 (1,093) 1,846
Net loss $ (11,208) $ (3,695) $ (31,637) $ (14,412)
Net loss per common share - basic (in dollars per share) $ (0.65) $ (0.44) $ (2.30) $ (1.94)
Net loss per common share - diluted (in dollars per share) $ (0.65) $ (0.44) $ (2.30) $ (1.94)
Weighted average number of common shares outstanding - basic (in shares) 17,218 8,352 13,748 7,445
Weighted average number of common shares outstanding - diluted (in shares) 17,218 8,352 13,748 7,445